Earnings ·
CAMP4 Therapeutics reports $29M Q3 net loss; raises $50.1M via private placement
CAMPCamp4 Therapeutics Corp
CAMP4 Therapeutics reported a net loss of $29.0 million for the third quarter ended September 30, 2026, an increase from $15.1 million in the prior-year period, driven largely by a $14.0 million non-cash charge related to changes in the fair value of derivative tranche liabilities. Research and development expenses rose to $11.4 million as the company advanced its ASCEND Phase 1/2 clinical trial for CMP-002, while general and administrative costs remained stable at $4.5 million. The firm also announced it received $50.1 million in gross proceeds from the second closing of a private placement, bringing total cash and cash equivalents to $124.5 million as of September 30, 2026. Management stated that current liquidity is sufficient to fund operations through the end of 2028. Additionally, CAMP4 received regulatory authorizations in the UK and EU to expand its global clinical trial for SYNGAP1-related disorder and plans to advance a SHANK3 program for Phelan-McDermid syndrome. CAMP4 Therapeutics is a clinical-stage biopharmaceutical company developing regulatory RNA-targeting therapeutics.